William Blair Estimates Repligen’s Q1 Earnings (NASDAQ:RGEN)

Repligen Co. (NASDAQ:RGEN) – Stock analysts at William Blair lowered their Q1 2025 earnings per share (EPS) estimates for Repligen in a research note issued to investors on Monday, March 10th. William Blair analyst M. Larew now anticipates that the biotechnology company will post earnings per share of $0.32 for the quarter, down from their previous estimate of $0.33. The consensus estimate for Repligen’s current full-year earnings is $1.72 per share. William Blair also issued estimates for Repligen’s Q3 2025 earnings at $0.42 EPS, FY2025 earnings at $1.67 EPS, Q3 2026 earnings at $0.59 EPS and FY2026 earnings at $2.30 EPS.

Several other analysts have also recently issued reports on RGEN. StockNews.com cut Repligen from a “hold” rating to a “sell” rating in a research note on Friday, February 21st. Canaccord Genuity Group assumed coverage on Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target on the stock. JPMorgan Chase & Co. raised their price target on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. Wolfe Research assumed coverage on Repligen in a research note on Thursday, November 14th. They issued a “peer perform” rating on the stock. Finally, Royal Bank of Canada raised their price target on Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a research note on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $181.00.

Repligen Stock Down 1.2 %

Shares of NASDAQ RGEN opened at $145.37 on Tuesday. The stock has a market cap of $8.14 billion, a P/E ratio of -285.04, a PEG ratio of 4.54 and a beta of 0.95. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. Repligen has a 12-month low of $113.50 and a 12-month high of $200.23. The business’s fifty day simple moving average is $157.18 and its 200-day simple moving average is $148.50.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.03. The business had revenue of $167.55 million for the quarter, compared to analysts’ expectations of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%.

Institutional Trading of Repligen

A number of hedge funds and other institutional investors have recently made changes to their positions in RGEN. QRG Capital Management Inc. increased its position in shares of Repligen by 12.5% during the third quarter. QRG Capital Management Inc. now owns 3,642 shares of the biotechnology company’s stock worth $542,000 after purchasing an additional 406 shares in the last quarter. Equitable Trust Co. grew its holdings in shares of Repligen by 52.8% during the third quarter. Equitable Trust Co. now owns 2,577 shares of the biotechnology company’s stock worth $384,000 after buying an additional 891 shares during the last quarter. Verdence Capital Advisors LLC grew its holdings in shares of Repligen by 20.6% during the third quarter. Verdence Capital Advisors LLC now owns 3,808 shares of the biotechnology company’s stock worth $567,000 after buying an additional 651 shares during the last quarter. Atria Investments Inc grew its holdings in shares of Repligen by 67.9% during the third quarter. Atria Investments Inc now owns 3,202 shares of the biotechnology company’s stock worth $477,000 after buying an additional 1,295 shares during the last quarter. Finally, Crossmark Global Holdings Inc. grew its holdings in shares of Repligen by 12.0% during the third quarter. Crossmark Global Holdings Inc. now owns 4,068 shares of the biotechnology company’s stock worth $606,000 after buying an additional 436 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.